Clinical trial
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006)…
NCT00483301 · Mt. Sinai Medical Center, Miami, Other · Completed
Key facts
| NCT number | NCT00483301 |
|---|---|
| Title | A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma |
| Official title | A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma |
| Lead sponsor | Mt. Sinai Medical Center, Miami, Other |
| Collaborators | Celgene Corporation Industry Bayer |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Drug |
| Interventions | Sorafenib (BAY 43-9006), ABI-007(Abraxane) |
| Enrollment | 34 |
| Start date | May 1, 2007 |
| Primary completion | Aug 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Jun 7, 2007 |
| Last update posted | May 3, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: